Entrada Therapeutics (TRDA) Preferred Stock Liabilities (2020 - 2021)
Entrada Therapeutics (TRDA) posted quarterly Preferred Stock Liabilities of $197.5 million for Q3 2021, up 141.85% year-over-year from $81.7 million in Q3 2020, and little changed quarter-over-quarter from $197.5 million in Q2 2021.
Powered by 
Analysis
Entrada Therapeutics (TRDA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Entrada Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $197.5 million for Q3 2021.
- In Q3 2021, Preferred Stock Liabilities rose 141.85% year-over-year to $197.5 million; the TTM figure through Sep 2021 stood at $197.5 million (up 141.85% YoY), while the FY2020 annual figure was $81.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2021 stood at $197.5 million, roughly flat from $197.5 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $197.5 million in Q1 2021, with the low at $81.7 million in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Entrada Therapeutics | 297.03 Mn | 297.03 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 197.49 Mn |
| Jun 30, 2021 | 197.49 Mn |
| Mar 31, 2021 | 197.49 Mn |
| Dec 31, 2020 | 81.66 Mn |
| Sep 30, 2020 | 81.66 Mn |